SCHEMBL21559634

SCHEMBL21559634

CC(C)n1nc(C(=O)OCc2ccccc2)cc1C(=O)OCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 1/20 0.46
TDP1 Q9NUW8 3/20 0.45
SLC6A2 P23975 1/20 0.45
SLC6A3 Q01959 1/20 0.45
KMT2A Q03164 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
MAPT P10636 3/20 0.44
ALDH1A1 P00352 3/20 0.43
RAB9A P51151 2/20 0.42
TSHR P16473 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAOB P27338 1/20 0.42
ADORA2A P29274 1/20 0.42
PKM P14618 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
SENP6 Q9GZR1 1/20 0.42
LMNA P02545 2/20 0.42
POLB P06746 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21290253 0.82 JMJD6 (0.51) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL20651058 0.80 TDP1 (0.46) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL19492477 0.78 TDP1 (0.47) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL5112110 0.77 HPGD (0.47) MAPTALDH1A1RAB9ATSHRMAOB
SCHEMBL5113571 0.77 HPGD (0.47) ALDH1A1TSHRKDM4EMAOBLMNA
SCHEMBL6482414 0.75 JMJD6 (0.45) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL30979681 0.75 KMT2A (0.42) KMT2AMAPTKDM4EADORA2ALMNA
SCHEMBL20651056 0.75 TDP1 (0.46) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL22005632 0.74 TDP1 (0.53) JMJD6TDP1SLC6A2SLC6A3KMT2A
SCHEMBL21559633 0.73 TDP1 (0.48) JMJD6TDP1SLC6A2SLC6A3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067629-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2024-02-29 US disclosed
US-11753399-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2023-09-12 US disclosed
US-11267801-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2022-03-08 US disclosed
US-20210171498-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2021-06-10 US disclosed
US-10836746-B2 Therapeutic compounds GILEAD SCIENCES, INC. (US) 2020-11-17 US disclosed
US-20190345136-A1 THERAPEUTIC COMPOUNDS GILEAD SCIENCES, INC. 2019-11-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11267801-B2 Therapeutic compounds NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885
US-20240067629-A1 THERAPEUTIC COMPOUNDS NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885
US-20210171498-A1 THERAPEUTIC COMPOUNDS NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885
US-10836746-B2 Therapeutic compounds NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885
US-20190345136-A1 THERAPEUTIC COMPOUNDS NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885
US-11753399-B2 Therapeutic compounds NPC1, CCR5, FURIN JMJD6 4134/4885TDP1 4124/4885SLC6A2 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.